Review
Technology evaluation: abatacept, Bristol-Myers Squibb
Affiliations
- PMID: 15264435
Item in Clipboard
Review
Technology evaluation: abatacept, Bristol-Myers Squibb
Curr Opin Mol Ther.
2004 Jun.
Abstract
Bristol-Myers Squibb is developing the fusion protein abatacept for the potential treatment of various immunological disorders, including rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. Abatacept is undergoing phase III clinical trials.
Similar articles
-
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.Arthritis Res Ther. 2005;7 Suppl 2(Suppl 2):S21-5. doi: 10.1186/ar1688. Epub 2005 Mar 16. Arthritis Res Ther. 2005. PMID: 15833145 Free PMC article. Review.
-
Technology evaluation: Belatacept, Bristol-Myers Squibb.Curr Opin Mol Ther. 2005 Aug;7(4):384-93. Curr Opin Mol Ther. 2005. PMID: 16121705
-
Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.Clin Immunol. 2007 May;123(2):190-8. doi: 10.1016/j.clim.2007.01.003. Epub 2007 Feb 23. Clin Immunol. 2007. PMID: 17321799
-
CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.J Leukoc Biol. 2005 Jul;78(1):144-57. doi: 10.1189/jlb.1104644. Epub 2005 Mar 23. J Leukoc Biol. 2005. PMID: 15788440
-
T lymphocyte co-signaling pathways of the B7-CD28 family.Cell Mol Immunol. 2004 Feb;1(1):37-42. Cell Mol Immunol. 2004. PMID: 16212919 Review.
Cited by
-
Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.Drugs Aging. 2009;26(4):273-93. doi: 10.2165/00002512-200926040-00001. Drugs Aging. 2009. PMID: 19476397 Review.
-
Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.Front Microbiol. 2011 Sep 29;2:199. doi: 10.3389/fmicb.2011.00199. eCollection 2011. Front Microbiol. 2011. PMID: 22046170 Free PMC article.
-
Abatacept: the evidence for its place in the treatment of rheumatoid arthritis.Core Evid. 2008 Feb 29;2(3):163-72. Core Evid. 2008. PMID: 21221183 Free PMC article.
-
CD86 is an activation receptor for NK cell cytotoxicity against tumor cells.PLoS One. 2013 Dec 11;8(12):e83913. doi: 10.1371/journal.pone.0083913. eCollection 2013. PLoS One. 2013. PMID: 24349559 Free PMC article.
-
Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression.Sci Adv. 2022 Jul 22;8(29):eabn0071. doi: 10.1126/sciadv.abn0071. Epub 2022 Jul 22. Sci Adv. 2022. PMID: 35867788 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical